Posted by Michael Wonder on 08 Sep 2021
Ultragenyx Canada announces Health Canada approval of a second indication for Crysvita (burosumab injection) for the treatment of tumour induced osteomalacia in adults
7 September 2021 - Ultragenyx Pharmaceutical today announced that Crysvita (burosumab Injection) has been approved by Health Canada for the treatment of tumour induced osteomalacia in adults.
Crysvita is also approved for the treatment of X-linked hypophosphatemia.
